Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
To the Editor,
We performed a prospective study to assess the safety of ZA in patients with transfusion dependent thalassemia with osteoporosis/osteopenia. The Institute’s ethics committee approved the study. Twenty-seven patients (17 males) with median age of 18 years (16–38 Years) were enrolled. All patients were receiving 500 mg of calcium carbonate twice daily and 0.25 μg alfacalcidol once daily. Reconstituted ZA diluted with 100 ml of 0.9% w/v sodium chloride solution was given as a 15-min intravenous infusion.
Financial support was obtained from Shantha Biotech for DXA scans and zoledronic acid for these patients.
Compliance with Ethical Standards
Conflict of interests
All the authors declares that they have no conflict of interests.
Informed consent was obtained from all individual participants included in the study. This was part of DM thesis.
- 3.Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMedGoogle Scholar